uniQure Inc.

Contributing Author

Recent Articles by uniQure Inc.

Nov-06	uniQure to Announce Third Quarter 2025 Financial Results QURE GlobeNewswire
Nov-03	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease QURE GlobeNewswire
Sep-29	uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares QURE GlobeNewswire
Sep-25	uniQure Announces Pricing of Upsized $300 Million Public Offering QURE GlobeNewswire
Sep-24	uniQure Announces $200 Million Proposed Public Offering QURE GlobeNewswire
Sep-24	uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding QURE GlobeNewswire
Sep-24	uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease QURE GlobeNewswire
Sep-05	uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in a-Gal A Enzyme Activity in Patients with Fabry Disease QURE GlobeNewswire
Jul-29	uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress QURE GlobeNewswire
Jul-22	uniQure to Announce Second Quarter 2025 Financial Results QURE GlobeNewswire
Jun-11	uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer QURE GlobeNewswire
Jun-02	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease QURE GlobeNewswire
May-29	uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) QURE GlobeNewswire
May-09	uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress QURE GlobeNewswire
May-05	uniQure to Announce First Quarter 2025 Financial Results QURE GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.